Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

22nd October 2019 Uncategorised 0

Sanofi is playing catch-up in gene therapy, but new CEO Paul Hudson is taking quick steps to close the gap. A reorganization of the R&D unit is intended to pivot the drugmaker toward immuno-oncology drugs and gene therapies. And to hasten the transition, the company is retrofitting a vaccine plant in France into a gene therapy manufacturing operation.

More: Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies
Source: fierce